| Identification | Back Directory | [Name]
N-(4-((1R,3S,5S)-3-amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide | [CAS]
1210608-43-7 | [Synonyms]
PIM447
EOS-60671
PIM447 (LGH447)
PIM447 (LGH447) Free Base
N-(4-((1R,3S,5S)-3-amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide
2-Pyridinecarboxamide, N-[4-[(1R,3S,5S)-3-amino-5-methylcyclohexyl]-3-pyridinyl]-6-(2,6-difluorophenyl)-5-fluoro- | [Molecular Formula]
C24H23F3N4O | [MOL File]
1210608-43-7.mol | [Molecular Weight]
440.46 |
| Chemical Properties | Back Directory | [Boiling point ]
493.7±45.0 °C(Predicted) | [density ]
1.290±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:88.0(Max Conc. mg/mL);199.79(Max Conc. mM)
Ethanol:88.0(Max Conc. mg/mL);199.79(Max Conc. mM) | [form ]
Solid | [pka]
1.35±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
PIM kinases promote growth and survival of tumor cells and are expressed in a wide variety of human cancers. These kinases are potential therapeutic targets. PIM447 is a PIM kinase inhibitor. | [in vivo]
PIM447 (100 mg/kg; p.o.; 5 times for a week) reduces tumor burden[2]. | Animal Model: | 6-week-old female NOD-SCID-IL-2Rγ?/??(NSG) mice (bearing RPMI-8226-luc cells)[2] | | Dosage: | 100 mg/kg | | Administration: | p.o.; 5 times for a week | | Result: | Clearly controlled tumor progression as measured by bioluminescence.? |
| [IC 50]
PIM1; PIM2; PIM3 |
|
|